Previously known as SN7618, chloroquine has been used since the early 1940s for the treatment of malaria [1]. In 1946 Loeb F. et al., in a statement approved by the board for coordination of malarial studies, highlighted the efficacy and safety profile of the drug – “with minor side effects as mild and transient headache, visual disturbances, pruritus, and gastrointestinal complaints”. The authors also noted that none of the adverse symptoms was serious and all of them were readily reversible [2].
